Current filters:


US FDA modifies dosing for ESA’s Aranesp, Epogen and Procrit on cardiovascular risks


The US Food and Drug Administration on Friday recommended more conservative dosing guidelines for erythropoiesis-stimulating…

AmgenAranespBiotechnologyEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients


An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical…

AmgenAranespBiotechnologyEpogenImmunologicalsJohnson & JohnsonOncologyPharmaceuticalProcritRegulation

Further re-evaluation of ESA anemia drugs proposed by US FDA officials


In An article published in the prestigious New England Journal of Medicine yesterday, a US Food and Drug…

AmgenAranespBiotechnologyDarbepoetin AlfaEpoetin AlfaEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

Amgen’s Aranesp did not meet endpoints and increased risk of stroke; firm accused of kickbacks


Leading US biotechnology firm Amgen suffered a double dose of bad news on October 30, when the firm revealed…

AmgenAranespBiotechnologyDarbepoetin AlfaGeneralNorth AmericaOncologyRegulation

Back to top